{"nctId":"NCT00525824","briefTitle":"12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTORâ„¢) in Combination With Ezetimibe","startDateStruct":{"date":"2007-08"},"conditions":["Hypercholesterolemia","Coronary Heart Disease","Atherosclerosis"],"count":1743,"armGroups":[],"interventions":[{"name":"Rosuvastatin (Crestor)","otherNames":[]},{"name":"Ezetimibe","otherNames":[]},{"name":"Simvastatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with with hypercholesterolaemia and CHD or a CHD risk equivalent, clinical evidence of atherosclerosis or a Framingham 10-year CHD risk score of \\>20\n* Patients will need to sign an informed consent before any visit procedures can be performed, including procedures for the optional genetic research and biomarker studies.\n* Patients must be 18 years or older and will be asked to stop taking any current cholesterol-lowering medications. Dietary counselling will be provided which will include an overview of the Therapeutic Lifestyle Change (TLC) diet the patients will be asked to follow\n\nExclusion Criteria:\n\n* Use of lipid lowering drugs and other prohibited concomitant medications. History of statin-induced myopathy, or serious hypersensitivity reaction to other HMG-CoA reductase inhibitors (statins), including rosuvastatin, simvastatin and/or a history of hypersensitivity to any components of ezetimibe.\n* Patients considered to be unstable by their physician after the following events:\n\na myocardial infarction, recent episode of unstable angina, myocardial revascularisation \\[percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft (CABG) surgery or another revascularisation procedure\\] or a transient ischaemic attack (TIA) or stroke and patients awaiting a planned myocardial revascularisation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment","description":"Percent change in LDL-C = (Combination treatment value - Baseline value)/Baseline value\\*100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-59.7200","spread":"14.1660"},{"groupId":"OG001","value":"-63.4800","spread":"16.6970"},{"groupId":"OG002","value":"-55.2200","spread":"15.7500"},{"groupId":"OG003","value":"-57.4200","spread":"20.4660"}]}]}]},{"type":"SECONDARY","title":"Percent Change in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks Combination Treatment","description":"Percent change in HDL-C = (Combination treatment value - Baseline value)/Baseline value\\*100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4100","spread":"13.9340"},{"groupId":"OG001","value":"7.4600","spread":"16.3510"},{"groupId":"OG002","value":"3.9200","spread":"12.6830"},{"groupId":"OG003","value":"4.3400","spread":"12.6430"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Total Cholesterol (TC) After 6 Weeks Combination Treatment","description":"Percent change in TC = (Combination treatment value - Baseline value)/Baseline value\\*100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.0000","spread":"11.2080"},{"groupId":"OG001","value":"-46.6300","spread":"12.8180"},{"groupId":"OG002","value":"-39.5600","spread":"12.6640"},{"groupId":"OG003","value":"-41.7100","spread":"15.1500"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Triglycerides (TG) After 6 Weeks Combination Treatment","description":"Percent change in TG = (Combination treatment value - Baseline value)/Baseline value\\*100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.8500","spread":"23.7090"},{"groupId":"OG001","value":"-35.0000","spread":"23.9710"},{"groupId":"OG002","value":"-22.9500","spread":"28.1390"},{"groupId":"OG003","value":"-25.8200","spread":"26.6190"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Non-high-density Lipoprotein Cholesterol (nonHDL-C) After 6 Weeks Combination Treatment","description":"Percent change in nonHDL-C = (Combination treatment value - Baseline value)/Baseline value\\*100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-54.6500","spread":"13.6770"},{"groupId":"OG001","value":"-58.9100","spread":"14.9320"},{"groupId":"OG002","value":"-49.9300","spread":"14.7380"},{"groupId":"OG003","value":"-52.3700","spread":"18.4290"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Apolipoprotein B (ApoB) After 6 Weeks Combination Treatment","description":"Percent change in ApoB = (Combination treatment value - Baseline value)/Baseline value\\*100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.1100","spread":"12.6280"},{"groupId":"OG001","value":"-49.5000","spread":"13.8210"},{"groupId":"OG002","value":"-41.9500","spread":"14.7500"},{"groupId":"OG003","value":"-44.1700","spread":"17.1790"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Apolipoprotein A1 (ApoA-1) After 6 Weeks Combination Treatment","description":"Percent change in ApoA-1 = (Combination treatment value - Baseline value)/Baseline value\\*100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8100","spread":"13.0420"},{"groupId":"OG001","value":"2.6800","spread":"11.5020"},{"groupId":"OG002","value":"1.4900","spread":"9.6830"},{"groupId":"OG003","value":"2.1300","spread":"10.7410"}]}]}]},{"type":"SECONDARY","title":"Percent Change in TC/HDL-C After 6 Weeks Combination Treatment","description":"Percent change in TC/HDL-C = (Combination treatment value - Baseline value)/Baseline value\\*100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.5200","spread":"13.2280"},{"groupId":"OG001","value":"-49.4600","spread":"13.5750"},{"groupId":"OG002","value":"-41.2700","spread":"13.0210"},{"groupId":"OG003","value":"-43.4500","spread":"16.3430"}]}]}]},{"type":"SECONDARY","title":"Percent Change in LDL-C/HDL-C After 6 Weeks Combination Treatment","description":"Percent change in LDL-C/HDL-C = (Combination treatment value - Baseline value)/Baseline value\\*100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-61.4700","spread":"15.5470"},{"groupId":"OG001","value":"-65.2500","spread":"16.6800"},{"groupId":"OG002","value":"-57.1300","spread":"14.7770"},{"groupId":"OG003","value":"-58.6600","spread":"21.1300"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Non-HDL-C/HDL-C After 6 Weeks Combination Treatment","description":"Percent change in non-HDL-C/HDL-C = (Combination treatment value - Baseline value)/Baseline value\\*100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-56.4200","spread":"15.4150"},{"groupId":"OG001","value":"-60.8900","spread":"15.5030"},{"groupId":"OG002","value":"-51.1100","spread":"15.3800"},{"groupId":"OG003","value":"-53.5100","spread":"20.2230"}]}]}]},{"type":"SECONDARY","title":"Percent Change in ApoB/ApoA-1 After 6 Weeks Combination Treatment","description":"Percent change in ApoB/ApoA-1 = (Combination treatment value - Baseline value)/Baseline value\\*100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-47.3900","spread":"13.8690"},{"groupId":"OG001","value":"-50.2400","spread":"14.2570"},{"groupId":"OG002","value":"-42.5400","spread":"14.2480"},{"groupId":"OG003","value":"-44.7600","spread":"17.8420"}]}]}]},{"type":"SECONDARY","title":"Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) After 6 Weeks Combination Treatment","description":"Percent change in hs-CRP = (Combination treatment value - Baseline value)/Baseline value\\*100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107.1200","spread":"-99.0000"},{"groupId":"OG001","value":"-9.5300","spread":"-97.9000"},{"groupId":"OG002","value":"15.0300","spread":"-91.5000"},{"groupId":"OG003","value":"0.4200","spread":"-94.9000"}]}]}]},{"type":"SECONDARY","title":"Percent Change in LDL-C After 6 Weeks Monotherapy","description":"Percent change in LDL-C = (Monotherapy treatment value - Baseline value)/Baseline value\\*100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.4900","spread":"13.1080"},{"groupId":"OG001","value":"-53.5900","spread":"10.5030"},{"groupId":"OG002","value":"-40.8600","spread":"12.4130"},{"groupId":"OG003","value":"-46.3500","spread":"16.1880"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3},"commonTop":["Myalgia","Nasopharyngitis","Headache","Arthralgia","Nausea"]}}}